University of California, San Francisco
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
Human Papilloma Virus
Warts
Warts, Genital
Condyloma
Condylomata acuminata
nonavalent human papillomavirus vaccine
PHASE1
PHASE2
This is a prospective, open-label, proof-of-concept research study to assess the effectiveness of intralesional nonavalent in the treatment of patients with genital condylomata. The study will be conducted at Zuckerberg San Francisco General Hospital. The planned intervention is to provide 10 subjects with at least 3 genital condylomata with intralesional nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for change in wart size and wart number.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 10 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Therapeutic Intralesional Nonavalent HPV Vaccine for Genital Condylomata in Adults: an Open Label Pilot Study |
Actual Study Start Date : | 2022-04-15 |
Estimated Primary Completion Date : | 2024-07-01 |
Estimated Study Completion Date : | 2024-07-01 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Zuckerberg San Francisco General Hospital
San Francisco, California, United States, 94110